Figures at a glance

Figure 1

Figure 2

Figure 3

Figure 4

FIGURE 1

Figure 1: NCOA4 expression is downregulated in glioma cell lines and specimens. (A)The protein level of NCOA4 was analyzed in glioma cell lines (A172, U87, 23N, SHG44, T98G, LN18, TJ899, B2-17, U251 and SNB19) and astrocytes. (B)The protein expression of NCOA4 was analyzed in glioma tissues and nontumorous brain tissues.

FIGURE 2

Figure 2: NCOA4 suppresses the growth of glioma cells. (A,B) NCOA4 knockdown and overexpression in LN18 and T98G cells. CCK-8 assays after NCOA4 knockdown and overexpression in glioma cell lines. (*, P< 0.05; **, P< 0.01 compared with control group.)

FIGURE 3

Figure 3: NCOA4 promotes TMZ-mediated inhibition of proliferation and invasion ability in glioma cells. (A) CCK-8 assays of DMSO group, TMZ group and Adv-NCOA4+TMZ group in LN18 and T98G cell lines. (B) Transwell assays of DMSO group, TMZ group and Adv-NCOA4+TMZ group in LN18 and T98G cell lines. *, P< 0.05; **, P< 0.01, compared with the DMSO group. #, P< 0.05; ##, P< 0.01, compared with the Adv-NCOA4

FIGURE 4

Figure 4: NCOA4 inhibits GSH and promotes ROS accumulation (A) Relative GSH levels were assessed using GSH Detection Kit. ( *, P< 0.05; **, P< 0.01 compared with control group.) (B) ROS levels of were assessed using the DCFDA assay.